Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by the excessive deposition of extracellular matrix (ECM), which is thought to contribute to this tumor’s malignant behavior. However, the detailed mechanism and the contribution of excessive deposition of ECM in PDAC progression remain unclear. A better understanding of the mechanism involved in this process is essential for the design of new effective therapies. In this study, we demonstrated that pancreatic cancer cells exhibited increased proliferation and decreased apoptosis in response to type I collagen. In addition, PDAC cells exposed to type I collagen lost the expression of E-cadherin and increased expression of mesenchymal markers, including N-cadherin and vimentin. This epithelial- mesenchymal transition (EMT) was correlated with enhanced cell migration and invasiveness. Knockdown of β1-integrin abolished the effects induced by type I collagen, and further investigation revealed that type I collagen activates β1-integrin (marked by phosphorylation of β1 integrin downstream effectors, focal adhesion kinase [FAK], AKT, and ERK) accompanied by markedly up-regulation of Gli-1, a component of the Hedgehog (HH) pathway. Knockdown of Gli-1 reversed the effects of type I collagen on PDAC invasion and EMT. These results suggest that there is cross-talk between the β1-integrin signaling pathway and the HH pathway in pancreatic cancer and that activation of the HH pathway plays a key role in the type I collagen-induced effects on pancreatic cancer.
Keywords: Desmoplastic reaction, epithelial–mesenchymal transition, extracellular matrix, hedgehog pathway, β1-integrin, pancreatic cancer.
Current Cancer Drug Targets
Title:The Activation of β1-integrin by Type I Collagen Coupling with the Hedgehog Pathway Promotes the Epithelial-Mesenchymal Transition in Pancreatic Cancer
Volume: 14 Issue: 5
Author(s): Wanxing Duan, Jiguang Ma, Qingyong Ma, Qinhong Xu, Jianjun Lei, Liang Han, Xuqi Li, Zheng Wang, Zheng Wu, Shifang Lv, Zhenhua Ma, Mouzhu Liu, Fengfei Wang and Erxi Wu
Affiliation:
Keywords: Desmoplastic reaction, epithelial–mesenchymal transition, extracellular matrix, hedgehog pathway, β1-integrin, pancreatic cancer.
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is characterized by the excessive deposition of extracellular matrix (ECM), which is thought to contribute to this tumor’s malignant behavior. However, the detailed mechanism and the contribution of excessive deposition of ECM in PDAC progression remain unclear. A better understanding of the mechanism involved in this process is essential for the design of new effective therapies. In this study, we demonstrated that pancreatic cancer cells exhibited increased proliferation and decreased apoptosis in response to type I collagen. In addition, PDAC cells exposed to type I collagen lost the expression of E-cadherin and increased expression of mesenchymal markers, including N-cadherin and vimentin. This epithelial- mesenchymal transition (EMT) was correlated with enhanced cell migration and invasiveness. Knockdown of β1-integrin abolished the effects induced by type I collagen, and further investigation revealed that type I collagen activates β1-integrin (marked by phosphorylation of β1 integrin downstream effectors, focal adhesion kinase [FAK], AKT, and ERK) accompanied by markedly up-regulation of Gli-1, a component of the Hedgehog (HH) pathway. Knockdown of Gli-1 reversed the effects of type I collagen on PDAC invasion and EMT. These results suggest that there is cross-talk between the β1-integrin signaling pathway and the HH pathway in pancreatic cancer and that activation of the HH pathway plays a key role in the type I collagen-induced effects on pancreatic cancer.
Export Options
About this article
Cite this article as:
Duan Wanxing, Ma Jiguang, Ma Qingyong, Xu Qinhong, Lei Jianjun, Han Liang, Li Xuqi, Wang Zheng, Wu Zheng, Lv Shifang, Ma Zhenhua, Liu Mouzhu, Wang Fengfei and Wu Erxi, The Activation of β1-integrin by Type I Collagen Coupling with the Hedgehog Pathway Promotes the Epithelial-Mesenchymal Transition in Pancreatic Cancer, Current Cancer Drug Targets 2014; 14 (5) . https://dx.doi.org/10.2174/1568009614666140402105101
DOI https://dx.doi.org/10.2174/1568009614666140402105101 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design, Synthesis and Biological Evaluation of Camptothecin Conjugated with NSAIDs as Novel Dual-actin Antitumor Agents
Letters in Drug Design & Discovery The Design of Clinical Trials for New Molecularly Targeted Compounds: Progress and New Initiatives
Current Pharmaceutical Design The 4-Quinolone-3-Carboxylic Acid Motif as a Multivalent Scaffold in Medicinal Chemistry
Current Medicinal Chemistry Curcuminoid Metabolism and its Contribution to the Pharmacological Effects
Current Drug Metabolism Effects of BCR-ABL Inhibitors on Anti-Tumor Immunity
Current Medicinal Chemistry Neurokinin Receptors and Subtypes as Potential Targets in Breast Cancer: Relevance to Bone Marrow Metastasis
Drug Design Reviews - Online (Discontinued) New Targets for Therapy in Polyglutamine (polyQ) Expansion Diseases
Current Drug Therapy Editorial [Hot topic: Newly Recognized Actions of Vitamin D3 (Guest Editor: Ilka Nemere)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Status and Perspectives of Stem Cell Based Therapies for Liver Diseases
Recent Patents on Regenerative Medicine Study of Parasitic Infections, Cancer, and other Diseases with Mass-Spectrometry and Quantitative Proteome-Disease Relationships
Current Proteomics The Epithelial-Mesenchymal Transition Pathway in Two Cases with Gastric Metastasis Originating from Breast Carcinoma, One with a Metachronous Primary Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery Editorial [ Apoptotic Pathways as Targets for Therapeutic Intervention Guest Editor: Domagoj Vucic ]
Current Cancer Drug Targets Synthesis of 4-substituted-3-hydroxy-5-oxo-10-oxa-4-azatricyclo[5.2.1]dec- 3-yl Acetic Acid Ethyl Esters as Norcantharidin Analogues
Letters in Drug Design & Discovery Fluorescein-Inspired Near-Infrared Chemodosimeter for Luminescence Bioimaging
Current Medicinal Chemistry Interventions Against Sarcopenia in Older Persons
Current Pharmaceutical Design Risk Factors for Myocardial Infarction in Women and Men: A Review of the Current Literature
Current Pharmaceutical Design An <i>In vivo</i> Immunohistochemical Study on MacroH2A.1 in Lung and Lymph-Node Tissues Exposed to an Asbestiform Fiber
Current Molecular Medicine Kinase Inhibitor Indole Derivatives as Anticancer Agents: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Discussion on Pharmacogenetic Interaction in G6PD Deficiency and Methods to Identify Potential Hemolytic Drugs
Cardiovascular & Hematological Disorders-Drug Targets Spectroscopic Characterization of a Pyridine Alkaloid from an Endophytic Strain of the Fusarium incarnatum-equiseti Species Complex
Current Bioactive Compounds